Predicting Low-Risk Febrile Neutropenia in Chemotherapy-Treated Patients With AML
Posted: Thursday, November 19, 2020
Approximately 13% of hospital admissions of chemotherapy-treated patients with acute myeloid leukemia (AML) for febrile neutropenia were considered to be “short and uncomplicated,” according to retrospective study findings presented at the 2020 Society of Hematologic Oncology (SOHO) Annual Meeting (Abstract AML-225). Although patients with a prior transplant were more likely to be hospitalized for shorter periods, no other factors predicted an “uncomplicated” stay, noted Anna B. Halpern, MD, of the University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, and colleagues.
“A model of combined risk factors resulted in a moderate-high predictive ability for a ‘low-risk’ admission,” the authors concluded.
In this study, the authors identified 250 instances among 129 patients with AML hospitalized for febrile neutropenia. Those patients presented with a temperature of more than 38.3°C and an absolute neutrophil count of fewer than 1,000 cells cells/μL following intensive chemotherapy. Low-risk patients were defined as those discharged within 72 hours of admission without requiring intensive care unit treatment.
The authors found that 13% of all patients (217 patients) admitted stayed fewer than 3 days. Those who stayed more than 3 days (33 patients) were more likely to have an infection identified (60%) than those with shorter stays (36%), but there were no differences in 30-day mortality. Additionally, no single factor predicted an “uncomplicated” admission in univariate analysis, the authors said.
Disclosure: No disclosure information for the study authors was provided.